Interaction of the Efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 294-306

  Eadie, L N ^a,b   Hughes, T P ^a,b,c   White, D L ^a,b,c  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; ENZYME INHIBITORS; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 84894413523     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.208     Document Type: Review

References (75)

1. Jabbour, E., Cortes, J.E. & Kantarjian, H.M. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin. Proc. 84, 161-169 (2009).
2. White, D.L. et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J. Clin. Oncol. 28, 2761-2767 (2010).
3. White, D. et al. ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance. ASH Ann. Meet. Abst. 108, 2144 (2006).
4. Szakacs, G., Varadi, A., Ozvegy-Laczka, C. & Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 13, 379-393 (2008).
5. Shapiro, A.B. & Ling, V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250, 130-137 (1997).
6. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M.M. & Ambudkar, S.V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94, 10594-10599 (1997).
7. Higgins, C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446, 749-757 (2007).
8. Eckford, P.D. & Sharom, F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109, 2989-3011 (2009).
9. Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
10. Dezi, M. et al. The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes. Biochim. Biophys. Acta 1798, 2094-2101 (2010).
11. McDevitt, C.A. et al. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14, 1623-1632 (2006).
12. Clark, R., Kerr, I.D. & Callaghan, R. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br. J. Pharmacol. 149, 506-515 (2006).
13. Choo, E.F. et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 28, 655-660 (2000).
14. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J.H., Borst, P. & Schinkel, A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100, 2430-2436 (1997).
15. Smith, A.J. et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. 275, 23530-23539 (2000).
16. Rautio, J. et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos. 34, 786-792 (2006).
17. Scharenberg, C.W., Harkey, M.A. & Torok-Storb, B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512 (2002).
18. Ozvegy-Laczka, C. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65, 1485-1495 (2004).
19. Luo, F.R., Paranjpe, P.V., Guo, A., Rubin, E. & Sinko, P. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab. Dispos. 30, 763-770 (2002).
20. Pauli-Magnus, C., Rekersbrink, S., Klotz, U. & Fromm, M.F. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 364, 551-557 (2001).
21. Breedveld, P. et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65, 2577-2582 (2005).
22. White, D.L., Eadie, L.N., Saunders, V.A., Hiwase, D.K. & Hughes, T.P. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia 27, 1201-1204 (2013).
23. Suzuki, K. et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol. 67, 44-49 (2009).
24. Breedveld, P. et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64, 5804-5811 (2004).
25. Allen, J.D. et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1, 417-425 (2002).
26. Weiss, J. et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. ntimicrob. Chemother. 59, 238-245 (2007).
27. Ozvegy, C. et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 285, 111-117 (2001).
28. Rabindran, S.K., Ross, D.D., Doyle, L.A., Yang, W. & Greenberger, L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60, 47-50 (2000).
29. Evers, R. et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 83, 375-383 (2000).
30. Flanagan, S.D., Cummins, C.L., Susanto, M., Liu, X., Takahashi, L.H. & Benet, L.Z. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 64, 126-134 (2002).
31. Peng, B. et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22, 935-942 (2004).
32. Picard, S. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496-3499 (2007).
33. Larson, R.A. et al.; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022-4028 (2008).
34. Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).
35. O'Hare, T., Eide, C.A. & Deininger, M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110, 2242-2249 (2007).
36. Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006).
37. Tanaka, C. et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther. 87, 197-203 (2010).
38. Hughes, T. et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 27, 4204-4210 (2009).
39. O'Hare, T. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505 (2005).
40. Australian Government -Department of Health and Ageing TGA. Australian Public Assessment Report for Dasatinib, 2011. http://www.tga.gov.au/auspar/ auspar-dasatinib-110711.htm.
41. Yin, O.Q. et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother. Pharmacol. 70, 345-350 (2012).
42. White, D., Saunders, V., Quinn, S., Manley, P. & Hughes, T. Proton pump inhibitors interact with transport of both imatinib and nilotinib. AACR Meet. Abst. 2007, 1635 (2007).
43. Burger, H. et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol. Ther. 4, 747-752 (2005).
44. Hirayama, C. et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm. Res. 25, 827-835 (2008).
45. Mahon, F.X. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 (2003).
46. Mahon, F.X. et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070-1079 (2000).
47. Gromicho, M. et al. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk. Lymphoma 52, 1980-1990 (2011).
48. Tang, C. et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk. Lymphoma 52, 2139-2147 (2011).
49. Gardner, E.R., Sparreboom, A., Verweij, J. & Figg, W.D. Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol. Ther. 7, 412-415 (2008).
50. White, D. et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106, 2520-2526 (2005).
51. Eadie, L.N., Saunders, V.A., Hughes, T.P. & White, D.L. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leuk. Lymphoma 54, 569-578 (2013).
52. Hegedus, T., Orfi, L., Seprodi, A., Varadi, A., Sarkadi, B. & Keri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 1587, 318-325 (2002).
53. Widmer, N., Colombo, S., Buclin, T. & Decosterd, L.A. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 102, 1142 (2003).
54. Illmer, T. et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18, 401-408 (2004).
55. Hamada, A., Miyano, H., Watanabe, H. & Saito, H. Interaction of imatinib mesilate with human P-glycoprotein. J. Pharmacol. Exp. Ther. 307, 824-828 (2003).
56. Giannoudis, A., Davies, A., Lucas, C.M., Harris, R.J., Pirmohamed, M. & Clark, R.E. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112, 3348-3354 (2008).
57. Dai, H., Marbach, P., Lemaire, M., Hayes, M. & Elmquist, W.F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 304, 1085-1092 (2003).
58. Dohse, M. et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos. 38, 1371-1380 (2010).
59. Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 215, 403-410 (1990).
60. Brendel, C. et al. Imatinib mesylate and nilotinib (AMN107) exhibit highaffinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21, 1267-1275 (2007).
61. Hegedus, C. et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol. 158, 1153-1164 (2009).
62. Mahon, F.X. et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 68, 9809-9816 (2008).
63. Davies, A. et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23, 1999-2006 (2009).
64. Tiwari, A.K. et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 78, 153-161 (2009).
65. Hiwase, D.K., White, D., Zrim, S., Saunders, V., Melo, J.V. & Hughes, T.P. Nilotinibmediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 24, 658-660 (2010).
66. Hiwase, D.K., Saunders, V.A., Nievergall, E., Ross, D.D., White, D.L. & Hughes, T.P. Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. Haematologica 98, 896-900 (2013).
67. Hiwase, D.K. et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res. 14, 3881-3888 (2008).
68. Chen, Y., Agarwal, S., Shaik, N.M., Chen, C., Yang, Z. & Elmquist, W.F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 330, 956-963 (2009).
69. Lagas, J.S. et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15, 2344-2351 (2009).
70. Nakanishi, T., Shiozawa, K., Hassel, B.A. & Ross, D.D. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108, 678-684 (2006).
71. Houghton, P.J. et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64, 2333-2337 (2004).
72. Burger, H. et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940-2942 (2004).
73. Jordanides, N.E., Jorgensen, H.G., Holyoake, T.L. & Mountford, J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108, 1370-1373 (2006).
74. Liu, W. et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin. Cancer Res. 13, 2463-2470 (2007).
75. Kern, E.H. and Di, L. Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. (Academic Press, Boston, 2008).